Skip to content
Back to news

Open Innovation: Servier supports several start-ups in their drive for therapeutic advancement

Since 2017, Servier has been a Gold sponsor of Lab Central, a leading shared lab space for biotechnology start-ups based in the heart of the Boston-Cambridge ecosystem in Massachusetts.

Each year, we award a Golden ticket in support of promising life science companies and entrepreneurs. Winners of the Golden Ticket receive $50,000 towards the purchase of space and services available at Lab Central over a 13-month period. The winning start-up will also benefit from close support Servier’s experienced teams, as well as access to the incubator’s shared infrastructure and to the large number of programs and services it offers.
In addition to the grant, Servier’s team of experts is on hand to provide the entrepreneurs with guidance and support in developing their projects.

This year, Servier awarded three Golden Tickets to start-ups in the US:

  • Vrata Therapeutics: Developing a next-generation nucleic acid (DNA or RNA) delivery platform to develop more potent genetic medicines through the direct nuclear delivery of therapeutics.
  • Grik Therapeutics: Through the combination of a novel biological mechanism and a powerful computational approach, they are developing a platform to modulate specific membrane proteins (ion channels) to treat a wide variety of diseases.
  • Deck Bio: Developing platform technologies for the rapid discovery and development of first-in-class biologics.

For the first time, Spartners by Servier & BioLabs, the start-up accelerator operated by BioLabs at the Servier R&D Institute in Paris-Saclay, has launched a Golden Ticket, to be presented on July 4, 2024.
This Golden Ticket will provide the winning start-up with a year’s hosting at Spartners, by Servier & BioLabs, a state-of-the-art accelerator dedicated to therapeutic innovation. 

This year’s lucky winner is They intend to develop new therapeutics by leveraging the power of protein modifications by the glycans (sugars) todeliver better treatment for patients.

The start-up is due to join Spartners by Servier & BioLabs form this summer. Benefits include access to equipped shared labs, events, and the BioLabs network, as well as Servier’s state-of-the-art labs, a network of mentors and industry experts, and essential operational resources to accelerate the development of their therapeutic innovation.

00:00 / 00:00
00:00 / 00:00

Spartners by Servier & BioLabs opened its doors in May 2023 shortly after the Servier R&D Institute opened on the Paris-Saclay Campus.

In just one year, Spartners by Servier & BioLabs has achieved:

  • 7 start-ups hosted
  • 1850m² of space with workbenches, high-tech equipment, and offices
  • Direct access to 1,200 experienced researchers at the Servier Paris-Saclay R&D Institute
  • Nearly a dozen selection committees

Servier is also a FAST Track partner of the California Life Sciences (CLS) FAST Advisory Program, which is dedicated to providing innovative biotech entrepreneurs with a customized advisory program to refine their business models, assess their strategic direction, make use of their intellectual property, and help them develop a milestone and scale-up plan with a view to raising capital.

In 2023, Servier supported Palm Therapeutics, which is developing targeted cancer therapies in areas of unmet patient needs. To achieve this, the start-up is focusing on palmitoylation, a protein modification process.

Servier sponsored Medicen to deliver 5 passes to participate in the BIO International Convention, the world’s foremost biotech meeting place, held in Boston from June 5-8, 2024.

Rosetta Omics, Altevax Biotech, Persea, WhiteLab Genomics and PEP-Therapy headed to the United States for the event, a unique opportunity to team up with the thousands of innovative players in the life sciences sector.